4d Molecular Therapeutics vs Septerna
4d Molecular Therapeutics is the larger business, with $85.2m of revenue in fiscal 2025 against $46.0m for Septerna (1.9 times as much). 4d Molecular Therapeutics grew faster (230194.6% against 4174.5%). Septerna kept more of each dollar of sales as profit: a net margin of -106.4% against -164.4%. 4d Molecular Therapeutics carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | 4d Molecular TherapeuticsFDMT, 2025 | SepternaSEPN, 2025 |
|---|---|---|
| Revenue | $85.2m | $46.0m |
| Revenue growth | 230194.6% | 4174.5% |
| Net income | −$140m | −$48.9m |
| Operating margin | -187.2% | -148.6% |
| Net margin | -164.4% | -106.4% |
| Return on equity | -27.6% | -12.2% |
| Free cash flow | −$110m | $110m |
| Cash | $60.2m | $121m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 196 | 130 |
| Market value | $656m | $1.98bn |
| Price vs our value range | — | Above our value range |
| Moat score | 12 (Weak) | — |
| Insider trades, 12 months | 0 buys, 25 sales | 0 buys, 28 sales |